Jubilant Pharmova Limited · NSE:JUBLPHARMA
Jubilant Pharmova — Q1 FY25 Earnings Presentation
73 slides from Jubilant Pharmova's earnings presentation, Jul 19, 2024
Slide 1: Cover letter to stock exchanges
July 19, 2024 BSE Limited, National Stock Exchange of India Limited, Floor 25, P. J. Towers Exchange Plaza, Bandra-Kurla Complex, Dalal Street, Fort Bandra (E), Mumbai - 400 001 Mumbai - 400051 Scrip Code: 530019 Symbol: JUBLPHARMA Dear Sirs, Sub: Press Release alongwith Earnings Presentation Ref: R
Slide 2: Jubilant Pharmova – Q1'FY25 Results press release
Jubilant Pharmova Limited 1A, Sector 16A, Noida – 201301, India Tel.: +91 120 4361000 PRESS RELEASE www.jubilantpharmova.com Noida, July 19, 2024 JUBILANT PHARMOVA – Q1’FY25 RESULTS Sustaining growth momentum, EBITDA margin expansion & Net debt/EBITDA reduction Particulars (Rs. Cr.) Q1’FY24 Q4’FY24
Slide 3: Segmental Business Performance
into a power purchase agreement and Security subscription and shareholder agreement with Isharays Energy Two Private Limited, for the purchase of renewable energy generated through captive power arrangement for its facilities located in Noida and Greater Noida. In January this year, the company appr
Slide 4: About Jubilant Pharmova Limited
Also, following the status change of the Solid dosage formulation facility at Roorkee, the exports to the US market are expected to increase in a meaningful and gradual manner. The business plans to launch 6 to 8 new products per annum in the US and other International markets. In Q1’FY25 revenue st
Slide 5: For more information, please contact: Disclaimer
For more information, please contact: For Investors Siddharth Rangnekar Pankaj Dhawan CDR India Phone: +91 120 436 1105 Phone: +91 97699 19966 E-mail: Pankaj.dhawan@jubl.com E-mail: siddharth@cdr-india.com For Media Ryan Marshall Gaurav Jain Madison Public Relations Phone: +91-120 436 1026 Phone: +9
Slide 6: Earnings Presentation Q1'FY25
Earnings Presentation Q1’FY25
Slide 7: Disclaimer
Disclaimer Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates f
Slide 8: Jubilant Bhartia Group - Snapshot
Jubilant Bhartia Group - Snapshot Jubilant Bhartia Group founded by Shyam S. Bhartia and Hari S. Bhartia, leading industrialists from India Strong presence in diverse sectors like Pharmaceuticals, Life Science Ingredients, Contract Research & Development Services and Therapeutics, Performance Polyme
Slide 9: Company Snapshot
Company Snapshot A global pharmaceutical company with strong team of approx. 5,500 multicultural people & Revenue at Rs. 6,703 Cr. (FY24) 1 2 3 4 5 6 Allergy CDMO PROPRIETARY Radiopharma CRDMO GENERICS Immunotherapy Sterile Injectables NEW DRUGS • Leading • # 2 Player in the US • Leading contract •
Slide 10: Revenue Split - Q1 FY25 (BU wise)
Revenue Split - Q1 FY25 ( BU wise ) 9% Radiopharma 14% Allergy Immunotherapy 48% CDMO - SI 19% CRDMO Generics 10% 5
Slide 11: Global Manufacturing & Research Footprint
Global Manufacturing & Research Footprint World class manufacturing facilities, 2 state of the art research centers & 46 radiopharmacies Kirkland, Montreal, Canada Kirkland, Montreal, Canada Spokane, Washington, USA Spokane, Washington, USA CDMO – SteriIe Injectables Radiopharmaceuticals CDMO – Ster
Slide 12: Jubilant Pharmova - Q1'FY25
Jubilant Pharmova - Q1’FY25 Announced Strategic Investments; Improved overall financial performance YoY 1 2 3 4 5 6 INNOVATE STRENGTHEN GROW BUILD STEER DISCOVER Allergy CDMO PROPRIETARY Sterile Injectables CRDMO GENERICS Radiopharma Immunotherapy NEW DRUGS • Continued growth • Continue to gain shar
Slide 13: Radiopharmaceuticals
1 Radiopharmaceuticals Growing role in treatment of life threatening diseases Single-photon Emission Positron Emission Radiopharmaceutical Computed Tomography Tomography Therapeutics (SPECT Imaging) (PET Imaging) (Tx) • Uses “low-energy” radio • Radiation is systemically or locally delivered • Uses
Slide 14: Radiopharmaceuticals: US market growth
Radiopharmaceuticals US radiopharmaceutical market is expected to reach approx. USD 20 Bn. by 2030, growing at a CAGR of 20 %+ US Radiopharmaceutical Market (USD Bn.) Growth Drivers and Key Trends • Growth driven by superior imaging and therapeutics profiles, new emerging isotopes with low off targe
Slide 15: Radiopharmaceuticals: Consolidated market with high entry barriers
Radiopharmaceuticals Consolidated market with high entry barriers Stringent manufacturing & regulatory environment Adherence with extensive license framework. Stringent manufacturing set up required to handle isotopes Managing time sensitive Forward integration logistics with radiopharmacies Radioac
Slide 16: Radiopharmaceuticals: Wide product portfolio
Radiopharmaceuticals We are one of largest manufacturer in the addressable market in the US with a wide radiopharmaceutical portfolio Organ Type Product Key Indication SPECT Tc99m-DTPA Pulmonary Embolism Key Differentiators Lung SPECT Tc99m-MAA Pulmonary Perfusion Localizing metastases • Diversified
Slide 17: Market leadership in MAA, DTPA and I-131
Radiopharmaceuticals Market leadership in select products - MAA, DTPA and I-131 Draximage ® MAA Draximage ® DTPA HICON® Sodium Iodine I 131 Solution USP MAA is used in the perfusion DTPA is used to assess HICON® is a radioactive phase of a ventilation/perfusion pulmonary ventilation function in ther
Slide 18: Innovation Leadership in Ruby-Fill
Radiopharmaceuticals Innovation Leadership in Ruby - Fill ®, Gaining market share consistently Growing Cardiac PET Market in the US Ruby-Fill ® Rubidium 82 generator and Elusion System ~420 • The RUBY-FILL® Rubidium 82 Generator ~375 contains accelerator produced Strontium-82, ~335 ~300 which decays
Slide 19: Ruby-Fill and Robust product pipeline
Radiopharmaceuticals Ruby-Fill® and Robust product pipeline to fuel future business growth New Product led volume Ruby-Fill® PET & SPECT Development of therapeutic growth Growth potential Product Pipeline product - MIBG • Gain market share in the • Target to launch new • Completed patient dosing gro
Slide 20: Radiopharmaceuticals: Driving revenue growth
Radiopharmaceuticals Driving revenue growth Particulars ( Rs. Cr.) Q1’FY24 Q4’FY24 Q1’FY25 Y-o-Y • Q1’FY25 revenue grew YoY on the back of new products sales in Sulfur colloid and growth in Ruby-Fill® Revenue 204 256 262 28% • Q1’FY25 EBITDA increased YoY on the back EBITDA 93 126 126 35% of increas
Slide 21: Radiopharmacy market outlook
Radiopharmacy US Radiopharmacy market is expected to grow on the back of novel PET & Therapeutic products SPECT Radiopharmacy PET Radiopharmacy Growth Drivers and Key Trends • Radiopharmacy dispenses and distributes radiopharmaceutical products • Consolidated market in US with top 3 radiopharmacy ne
Slide 22: Radiopharmacy: Consolidated market with high barriers to entry
Radiopharmacy Consolidated market with high barriers to entry Consolidated Market Barriers to Entry Stringent Regulations # of radio # of 1 pharmacies SPECT PET hospitals Each treatment site is required to obtain a license from pharmacies pharmacies served in in the US the US Nuclear Regulatory Comm
Slide 23: 2nd largest radiopharmacy network in the US
Radiopharmacy 2nd largest radiopharmacy network in the US 46 nuclear USP<825> pharmacies JDR network is USP 825 including SPECT Portland WD compliant. and PET MT ND ME OR MN VT ID Saginaw NH 1,800 SD Minneapolis WI Detroit Wilkes NY Boston >100 WY MI Phila- RI radiopharmaceutical number of Barre PA
Slide 24: Sofie transaction closed; investing in PET radiopharmacy network
Radiopharmacy Sofie transaction closed; Investing in PET radiopharmacy network throughout the US to drive growth & profitability Sofie (PET Radiopharmacy Network) merger transaction closed Plans to invest USD 50 million Investment generated multifold returns to strengthen PET radiopharmacy network t
Slide 25: Expand Radiopharmacy network
Radiopharmacy Expand Radiopharmacy network, Ride on volume & new product led industry growth Radiopharmacy Network New Product led volume Enhance Operational Expansion growth Efficiencies • Expand PET radiopharmacy • Drive revenue on the back of • Further strengthen performance network by adding six
Slide 26: Radiopharmacy: Volume to drive revenue growth
Radiopharmacy Volume to drive revenue growth & operational efficiency to drive margin expansion • Q1’FY25 revenue grew YoY on the back of Particulars ( Rs. Cr.) Q1’FY24 Q4’FY24 Q1’FY25 Y-o-Y increase in volume from new products Revenue 487 561 570 17% • Q1’FY25 EBITDA increased YoY on the back of in
Slide 27: Allergy Immunotherapy market
2 Allergy Immunotherapy Global market poised to reach USD 3 Bn. by 2028, growing at a CAGR of ~ 7% Most Common Allergies in US (2023) Global Allergy Immunotherapy Market ( USD Bn. ) Others Insect 6.4% 3.0 6.4% 2.2 Food 10.0% Pollen 2.7 40.0% 2.0 Pet 10.9% 0.2 0.3 Mold Drug 2023 2028 12.7% 13.6% Non-
Slide 28: Jubilant is #2 player in US SC allergy immunotherapy
Allergy Immunotherapy Jubilant is #2 player in the US Sub-Cutaneous Allergy Immunotherapy market with strong entry barriers Strong Entry Barriers Key Differentiators • Highly concentrated US market with well established • # 2 player in the US SCIT allergy market & Sole Supplier players of Venom immu
Slide 29: Balanced Product Portfolio
Allergy Immunotherapy Balanced Product Portfolio Venom Extracts Allergenic Extracts Skin Testing Devices • Allergenic extracts (over 200 • Multiple skin test system includes • Venom extracts includes products for ComforTen, Quintest and Quintip products) includes products for Honey Bee, White-Faced
Slide 30: Three pronged growth strategy
Allergy Immunotherapy Moving ahead on three pronged growth strategy Enlarge US Venom Segment Gain market share in US Penetrate outside US market Allergenic extracts • Create customer awareness on • Use Venom products to gain • Penetrate the Europe market on the the Bee sting allergy through customer
Slide 31: Allergy Immunotherapy: Sustained growth momentum
Allergy Immunotherapy Sustained growth momentum & margin expansion Particulars ( Rs. Cr.) Q1’FY24 Q4’FY24 Q1’FY25 Y-o-Y • Q1’FY25 revenue grew YoY on the back of volume & price increase Revenue 151 188 168 11% • Q1’FY25 EBITDA margin increased YoY due to increase in revenue and improvement in EBITDA
Slide 32: CDMO Sterile Injectables: Demand to outpace supply
3 CDMO - Sterile Injectables Demand expected to outpace the supply by FY’26 Global CDMO-SI Market Size (in USD Bn.) Growth Drivers & Key Trends 20 • Increase in demand: Increasing number of 17 drugs/injectable in development pipeline driven by 16 biologics (65%+ of current pipeline) and LOEs 14 13 •
Slide 33: Structurally attractive market with key differentiators
CDMO - Sterile Injectables Structurally attractive market with key differentiators driving our growth Strong Entry Barriers Key Differentiators • Majority of commercial contracts are typically long • Deep and long-term relationships with our customers duration (typically 3 years or more with auto re
Slide 34: Collaborative partner with unique capabilities
CDMO - Sterile Injectables Collaborative partner with unique capabilities & strong customer relationships Full Suite of • Can handle Vial size from 2ml to 100 ml with batch size up to 2,000 ltr. Services • Full suite of services including sterile fill and finish (Liquid & Freeze dried), Ophthalmic (
Slide 35: Doubling of capacity at Spokane on track
CDMO - Sterile Injectables Doubling of capacity with state of the art technology at Spokane on track Timeline FY’24 FY’25 FY’26 FY’27 FY’28 LINE 3 Installation Media Fill Commercial Production LINE 4 Design Construction Installation Media Fill Commercial Production • Doubling Spokane capacity of ste
Slide 36: CDMO Sterile Injectables: Driving Revenue growth
CDMO - Sterile Injectables Driving Revenue growth • Q1’FY25 revenue increased YoY due to increase in volume Particulars ( Rs. Cr.) Q1’FY24 Q4’FY24 Q1’FY25 Y-o-Y • Q1’FY25 EBITDA & EBITDA margins Revenue 254 259 324 27% increased YoY due to increase in revenue EBITDA 41 58 57 40% • Q1’FY25 EBITDA mar
Slide 37: CRDMO: Drug Discovery Services, CDMO & API
4 CRDMO: Drug Discovery Services, CDMO & API Both Drug Discovery Services and API/Formulation Development markets are expected to grow at ~5-6% CAGR Growth Drivers for Drug Discovery Market Drug Discovery Services Market Size (USD Bn.) 10 • Large Pharma companies to de-risk their supply chain by add
Slide 38: CDMO API market
CDMO API market CDMO API Market is estimated to grow at a CAGR of ~ 6%+ CDMO API Market Size (USD Bn.) Growth Drivers for API Market ~ 130 + • Although API market is dominated by the small molecules, higher growth is experienced by HPAPIs and large molecule segments 18 ~ 95 + 16 • Cost competitivene
Slide 39: End to end CRDMO services
CRDMO : Drug Discovery Services & API We provide end to end CRDMO services for drug substance in small molecules CRDMO - Drug Discovery Services CDMO CRDMO - API Integrated Chemistry Research Contract Development & Advanced Intermediate Drug Discovery Centre Innovation Centre Manufacturing Centre &
Slide 40: Drug Discovery Services: Three pronged growth strategy
Drug Discovery Services Three Pronged growth strategy Grow Diversify Drive Chemistry Services Customer Segment CDMO • Grow Chemistry services by • Diversify customer segment by • Drive CDMO: Building development offering differentiated services increasing the penetration at large capabilities and le
Slide 41: API: Maximize market penetration
API Maximize market penetration & Transform operations by increasing cost effectiveness & asset utilisation Dominant position in select therapies • Comprehensive portfolio comprising of APIs from various therapeutic area - Central Nervous System, Cardiovascular System, Anti-infective and Anti- diabe
Slide 42: CRDMO results
CRDMO DDS: Biotech Industry headwinds continues; Medium term outlook continues to be positive CRDMO API: Pricing pressure continues; Taking initiatives to reduce operating costs & increase capacity utilization Drug Discovery Services • Q1’FY25 revenue increased YoY due to higher Particulars ( Rs. Cr
Slide 43: Generics market
5 Generics Global market to grow at a CAGR of 5 to 6% in the next 5 years Generics Market (USD Bn.) Overall Market • Overall market is growing on the back of increase in Chronic disease prevalence, loss of exclusivity for innovator products negated by pricing pressure in select markets ~ 532 Develop
Slide 44: Generics: Target EBITDA breakeven within FY25
Generics Target to reach EBITDA breakeven within FY25 & then grow profitability in the medium term Key Products & Facilities • Therapeutic areas - Cardiovascular System, Central Nervous System, Gastrointestinal and Multi Specialty • Global presence with serving more than 50 countries including US, E
Slide 45: Growth Strategy for key markets
Generics Growth Strategy for key markets Grow the profitable Build business in Achieve profitability in the US Non-US International market Indian Market Market • Focus on scaling 2 key markets • Build and Scale branded • Focus on profitable sustainable to triple digit revenue in INR Cr. generics bus
Slide 46: Actions taken to propel US Generics towards profitability
Generics Actions taken to propel US Generics business towards profitability New Closure Productof ledIn-house volume Outsource manufacturing Grow through growth Operations Manufacturing to CMO’s launch of new products • Closure of manufacturing • Outsourced manufacturing to • Grow the exports from R
Slide 47: Lean & Agile operations through Roorkee & CMO Network
Generics Lean & Agile operations through facility in Roorkee & CMO Network Continuous De-risk Product supplies Continue Quality Improvement by outsourcing Cost Optimisation Implemented a large scale quality De-risking product supplies through Implemented cost optimization improvement program in Roor
Slide 48: Generics: Moving in the right direction
Generics Moving in the right direction; Expect to reach EBITDA breakeven within FY25 Particulars ( Rs. Cr.) Q1’FY24 Q4’FY24 Q1’FY25 Y-o-Y • Q1’FY25 revenue decreased due to lower sales in US as a result of focus on profitable products Revenue 202 201 156 (23%) • Q1’FY25 EBITDA improved YoY. Expect t
Slide 49: Proprietary Novel Drugs: Clinical stage precision therapeutics
6 Proprietary Novel Drugs Clinical stage precision therapeutics Advancing potent molecules to address unmet medical needs in Oncology & Auto immune diseases Lead Pre - Clinical Program Mechanism Indications Phase I /II Milestones Optimization (IND) ET(Essential Phase I data suggests thrombocythemia)
Slide 50: Key Indications for JBI-802
Proprietary Novel Drugs Key Indications for JBI - 802 Disease Indications Rationale JBI - 802 Response Non-Small cell lung cancer • STK11 mutation is observed in10-15% NSCLC (85 % of lung One patient with NSCLC having STK11 mutations showed (NSCLC) cancer is NSCLC). significant response on JBI-802,
Slide 51: Phase Two & Investigator led trials for JBI-802
Proprietary Novel Drugs Phase Two & Investigator led clinical trials to start for JBI-802 Product • JBI-802 Small molecule - CoREST Inhibitor Indications • Essential Thrombocythemia / Myeloproliferative Neoplasms • Lung cancer (NSCLC), Acute myeloid leukemia (AML) Scientific Rationale • CoREST inhib
Slide 52: Key Indications for JBI-778
Proprietary Novel Drugs Key Indications for JBI - 778 Disease Indications Rationale JBI – 778 Response Non-Small cell lung cancer • EGFR (epidermal growth factor receptor) mutations are • PRMT5 is involved in splicing Mutations (NSCLC) with or without brain observed in 10 - 50% of non-small cell lun
Slide 53: Proprietary Novel Drugs: Continue to invest
Proprietary Novel Drugs Continue to invest • Continue to invest in two clinical stage Particulars ( Rs. Cr.) Q1’FY24 Q4’FY24 Q1’FY25 Y-o-Y programs Revenue 0 0 0 N/A EBITDA (10) (7) (6) 39% 48
Slide 54: Consolidated Reported Financials - Q1'FY25
Consolidated Reported Financials - Q1’FY25 Total Income growth (YoY) along with EBITDA margin expansion (YoY) Particulars ( Rs. Cr. ) Q1’FY24 Q4’FY24 Q1’FY25 Y-o-Y • Q1’FY25 Total Income increased YoY on the Revenue 1,587 1,759 1,732 9% back of growth in revenue in Radiopharma, Allergy Immunotherapy
Slide 55: Key Ratios
Key Ratios Net Debt / Ebitda improved drastically post voluntary prepayment of USD 75 million debt Particulars ( Rs. Cr. ) Mar 31, 2024 June 30, 2024 • Prepaid debt of USD 75 Mn., equivalent to Rs. 626 Cr. in Q1’FY25 Net Debt ( On constant currency ) 2,509 1,869 Net Debt / Equity 0.46 0.32 Net Debt
Slide 56: Sustainability
Sustainability Signed PPA1 & SHA2 to purchase renewable energy for JPM entities in Noida and Greater Noida in Q1’FY25 Climate B Water B Supply Chain B Achieved 93 percentile Achieved 85 percentile 23709 patients consulted through 41.5 % reduction in Specific 22.5% reduction in Specific Water Jubicar
Slide 57: Summary - Q1'FY25
Summary - Q1’FY25 Radio Pharmaceuticals : New product, Sulfur Colloid and Ruby-Fill® driving growth momentum 1 Radio Pharmacies : Volume led growth & operational efficiencies driving margin expansion 2 Allergy Immunotherapy : Sustained growth momentum & EBITDA margins 3 CDMO Sterile Injectable : Cap
Slide 58: Financial Results Table
Financial Results Table Total Income ( Rs. Cr. ) Q1’FY24 Q4’FY24 Q1’FY25 Revenue (A) 1,587 1,759 1,732 a. Radiopharma 691 818 832 Radiopharmaceuticals 204 256 262 Radiopharmacies 487 561 570 b. Allergy Immunotherapy 151 188 168 c. CDMO Sterile Injectables 254 259 324 d. Generics 202 201 156 e. CRDMO
Slide 59: Annexure
Annexure
Slide 60: JPM Business Strategy
JPM Business Strategy To strengthen the unique position of each of the business unit to enhance shareholder value 1 2 3 4 5 6 INNOVATE STRENGTHEN GROW BUILD STEER DISCOVER Allergy CDMO PROPRIETARY Sterile Injectables CRDMO GENERICS Radiopharma Immunotherapy NEW DRUGS • Continue to grow • Gain share
Slide 61: Executive Leadership Team
Executive Leadership Team Shyam S Bhartia Hari S Bhartia Priyavrat Bhartia Arjun S Bhartia Chairman Co-Chairman Managing Director Joint Managing Director Arvind Chokhany Shantanu Jha Dr. Tushar Gupta Group CFO, Group CHRO SVP – Corporate Strategy 56 Whole-time Director
Slide 62: Executive Leadership Team
Executive Leadership Team Harsher Singh Kyle Ferguson Chris Preti CEO - Jubilant Radiopharma CEO – Allergy Business CEO - CDMO Giuliano Perfetti Dr. Jaidev Rajpal Dr. Syed Kazmi CEO - CRDMO, Biosys CEO - Jubilant Generics CEO - Jubilant Therapeutics 57
Slide 63: Shareholding Pattern
Shareholding Pattern As on 30th June 2024 0.6% 25.2% Promoter and Promoter Group Domestic Institutions 50.7% Foreign Institutions Non - Institutions Employee Benefit Trust 19.5% 4.1% 58
Slide 64: Glossary
GLOSSARY Abbreviation Details Abbreviation Details CVS Cardiovascular System MEA Middle East Africa CNS Central Nervous System LATAM Latin America CDMO Contract Development Manufacturing Organization LOE Loss of exclusivity CRDMO Contract Research & Development Manufacturing Organization FDA (US) U.
Slide 65: For More Information
For More Information For Investors: Pankaj Dhawan Siddharth Rangnekar Jubilant Pharmova Limited CDR India Ph: +91 120 436 1105 Ph: +91 +91 9769919966 E-mail: Pankaj.dhawan@jubl.com E-mail: siddharth@cdr-india.com For Media: Ryan Marshall Gaurav Jain Madison Public Relations Ph: +91 120 436 1026 E-ma
Slide 66: Q1'FY25 Q&A Disclaimer
Q1’FY25 Q&A Disclaimer Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and ta
Slide 67: Radiopharmaceuticals Q&A: Ruby-Fill growth
Radiopharmaceuticals Q1. Can you talk about growth in Ruby-Fill®? Answer: Coronary Artery disease is the most common type heart of disease in the US. Cardiac PET procedures in the US are expected to double over the next 5 years. Ruby-fill® is a best in class Positron Emission Tomography (PET) radiop
Slide 68: Q&A: Product pipeline and Radiopharmacy
Q4. Can you give us some more colour on the product pipeline? Answer: We have a very strong pipeline of products in SPECT (Addressable Market at approx. USD 50 million) & PET (Addressable Market at approx. USD 500 million) categories in the medium term. On top of it, in the therapeutic, we are worki
Slide 69: Q&A: Allergy Immunotherapy
in a few products. Q4’FY24 EBITDA margins were higher due to seasonality in the business. Allergy Immunotherapy Q9. What are the growth levers in this business? Answer: We have three growth levers in place. 1. US Venom: As you are aware, we are the sole player in this segment in the US, so we are do
Slide 70: Q&A: Spokane expansion project
Q12. What is the project status of the expansion project in Spokane? What is the maximum revenue potential for Line 3 & 4 and how much time it shall take to fill up the lines? Answer: The capacity expansion program in Spokane, Washington, USA is on track with respect to time and cost. Line 3 and Lin
Slide 71: Q&A: CRDMO Drug Discovery
money) from working with biotechnology service providers that are connected to foreign adversaries. We are very bullish on the prospects of the CRO industry in India due to talent availability & gradual shifting of demand due to the preference for friend “sourcing” locations. At Jubilant Pharmova, w
Slide 72: Q&A: Generics and new product launches
Also, following the status change of solid dosage formulation facility at Roorkee, the exports to the US market are expected to increase in a meaningful and gradual manner. The business plans to launch six to eight new products per annum in the US and other international markets. In our last update,
Slide 73: Q&A: Financial priorities
Answer: In Q1’FY25, Total income grew by 9% on a YoY basis to Rs. 1,746 Cr., EBITDA grew by 50% YoY basis to Rs. 266 Cr. due to improved performance across all businesses and net debt to EBITDA improved from 2.5x to 1.7x. Over the next quarter and in FY25, we shall continue to work on these three fi